Immunovant, Inc. (IMVT) Dividend History

Company News

• Why Immunovant Stock Blasted Higher Today

  Immunovant's stock gained 11% after reporting positive results from a proof-of-concept study for batoclimab, an investigational drug targeting Grave's disease. The study showed 17 out of 21 patients maintained normal thyroid function six months after treatment.

  The Motley Fool
• Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

  Immunovant presented promising six-month off-treatment data for batoclimab in Graves' disease, showing ~80% of patients maintained normal thyroid function and ~50% achieved anti-thyroid drug-free remission.

  GlobeNewswire Inc.

  Featured Companies: ROIV
• IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab

  Immunovant's (IMVT) investigational candidate, batoclimab, showed positive data in a mid-stage study for Graves' Disease, leading to a rise in the company's stock. The data demonstrated significant reductions in Immunoglobin G levels and high response rates in the patient population.

  Benzinga

  Featured Companies: FULC ILMN KRYS
• Immunovant (IMVT) Down 1.6% Since Last Earnings Report: Can It Rebound?

  Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  Zacks Investment Research